Journey Medical(DERM) 最新动态_F10_同花顺金融服务网

最新动态

每股收益： -0.43美元 [[[0,"-0.80"],[1,"-0.72"],[2,"-0.18"],[3,"-0.34"],[4,"-0.43"]],[[0,"2024\u4e09\u5b63\u62a5"],[1,"2024\u5e74\u62a5"],[2,"2025\u4e00\u5b63\u62a5"],[3,"2025\u4e2d\u62a5"],[4,"2025\u4e09\u5b63\u62a5"]],"\u7f8e\u5143"] 每股收益单位：美元查看明细>>	归母净利润： -1018.4万美元同比增长37.11% [[[0,"-1619.30"],[1,"-1467.20"],[2,"-407.30"],[3,"-786.90"],[4,"-1018.40"]],[[0,"2024\u4e09\u5b63\u62a5"],[1,"2024\u5e74\u62a5"],[2,"2025\u4e00\u5b63\u62a5"],[3,"2025\u4e2d\u62a5"],[4,"2025\u4e09\u5b63\u62a5"]],"\u4e07\u7f8e\u5143"] 净利润单位：万美元查看明细>>	每股净资产： 0.98美元 [[[0,"0.53"],[1,"0.91"],[2,"0.93"],[3,"0.82"],[4,"0.98"]],[[0,"2024\u4e09\u5b63\u62a5"],[1,"2024\u5e74\u62a5"],[2,"2025\u4e00\u5b63\u62a5"],[3,"2025\u4e2d\u62a5"],[4,"2025\u4e09\u5b63\u62a5"]],"\u7f8e\u5143"] 每股净资产单位：美元查看明细>>	净资产收益率ROE(平均)： -44.31% [[[0,"-19.58"],[1,"-40.03"],[2,"-44.31"]],[[0,"2025\u4e00\u5b63\u62a5"],[1,"2025\u4e2d\u62a5"],[2,"2025\u4e09\u5b63\u62a5"]],""] 总资产报酬率(ROE) 单位：% 查看明细>>
稀释每股收益： -0.43美元 [[[0,"-0.80"],[1,"-0.72"],[2,"-0.18"],[3,"-0.34"],[4,"-0.43"]],[[0,"2024\u4e09\u5b63\u62a5"],[1,"2024\u5e74\u62a5"],[2,"2025\u4e00\u5b63\u62a5"],[3,"2025\u4e2d\u62a5"],[4,"2025\u4e09\u5b63\u62a5"]],"\u7f8e\u5143"] 稀释每股收益单位：美元查看明细>>	营业收入： 4577.90万美元同比增长7.68% [[[0,"4251.40"],[1,"5613.40"],[2,"1313.90"],[3,"2814.80"],[4,"4577.90"]],[[0,"2024\u4e09\u5b63\u62a5"],[1,"2024\u5e74\u62a5"],[2,"2025\u4e00\u5b63\u62a5"],[3,"2025\u4e2d\u62a5"],[4,"2025\u4e09\u5b63\u62a5"]],"\u4e07\u7f8e\u5143"] 营业收入单位：万美元查看明细>>	每股现金流： -0.23美元 [[[0,"-0.55"],[1,"-0.41"],[2,"-0.12"],[3,"-0.16"],[4,"-0.23"]],[[0,"2024\u4e09\u5b63\u62a5"],[1,"2024\u5e74\u62a5"],[2,"2025\u4e00\u5b63\u62a5"],[3,"2025\u4e2d\u62a5"],[4,"2025\u4e09\u5b63\u62a5"]],"\u7f8e\u5143"] 每股现金流单位：美元查看明细>>	总资产收益率(ROA)： -12.31% [[[0,"-4.93"],[1,"-9.75"],[2,"-12.31"]],[[0,"2025\u4e00\u5b63\u62a5"],[1,"2025\u4e2d\u62a5"],[2,"2025\u4e09\u5b63\u62a5"]],""] 总资产收益率(ROA) 单位：% 查看明细>>

注释：公司货币计价单位为美元

近期重要事件

2025-11-12	详情>> 股本变动：变动后总股本2713.59万股
2025-11-12	详情>> 业绩披露： 2025年三季报(累计)每股收益-0.43美元,归母净利润-1018.4万美元,同比去年增长37.11%
2025-11-12	财报披露：美东时间 2025-11-12 盘后发布财报
2025-08-25	详情>> 内部人交易： Maraoui Claude共交易2笔
2025-08-12	详情>> 业绩披露： 2025年中报每股收益-0.34美元,归母净利润-786.9万美元,同比去年增长42.99%
2025-05-15	复牌提示： 2025-05-15 09:35:24 停牌，复牌日期 2025-05-15 09:40:24
2025-05-15	详情>> 业绩披露： 2025年一季报每股收益-0.18美元,归母净利润-407.3万美元,同比去年增长60.99%
2025-04-29	股东大会：将于2025-06-24召开股东大会会议内容 ▼▲ 1.Elect six directors for a term of one year until our 2026 Annual Meeting of Stockholders or until their successors are duly elected and qualified in accordance with our Bylaws; 2.Ratify the appointment of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2025; 3.Adopt and approve the Fourth Amended and Restated Certificate of Incorporation providing for, among other things, officer exculpation; 4.Transact any other business that may properly come before the Annual Meeting or any adjournment of the Annual Meeting.
2025-03-27	详情>> 业绩披露： 2024年年报每股收益-0.72美元,归母净利润-1467.2万美元,同比去年增长-280.79%
2024-11-12	详情>> 业绩披露： 2024年三季报(累计)每股收益-0.8美元,归母净利润-1619.3万美元,同比去年增长-846.96%
2024-08-13	详情>> 业绩披露： 2024年中报每股收益-0.69美元,归母净利润-1380.3万美元,同比去年增长25.39%
2024-05-14	详情>> 业绩披露： 2024年一季报每股收益-0.53美元,归母净利润-1044.2万美元,同比去年增长-3.02%
2024-04-29	股东大会：将于2024-06-25召开股东大会会议内容 ▼▲ 1.Elect five directors for a term of one year until our 2025 Annual Meeting of Stockholders or until their successors are duly elected and qualified in accordance with our Bylaws; 2.Ratify the appointment of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2024; 3.Approve an amendment to the Company’s 2015 Stock Incentive Plan, as amended, to increase the number of shares of the Company’s common stock issuable thereunder by 3,000,000 and extend the term of that plan by ten years; 4.Transact any other business that may properly come before the Annual Meeting or any adjournment of the Annual Meeting.
2024-03-29	详情>> 业绩披露： 2023年年报每股收益-0.21美元,归母净利润-385.3万美元,同比去年增长87.00%
2023-11-13	详情>> 业绩披露： 2023年三季报(累计)每股收益-0.09美元,归母净利润-171万美元,同比去年增长90.99%
2023-08-10	详情>> 业绩披露： 2023年中报每股收益-1.03美元,归母净利润-1849.9万美元,同比去年增长-107.71%
2023-04-28	股东大会：将于2023-06-21召开股东大会会议内容 ▼▲ 1.Elect six directors for a term of one year until our 2024 Annual Meeting of Stockholders or until their successors are duly elected and qualified in accordance with our Bylaws. 2.Ratify the appointment of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2023. 3.Approve the Journey Medical Corporation 2023 Employee Stock Purchase Plan. 4.Transact any other business that may properly come before the Annual Meeting or any adjournment of the Annual Meeting.
2022-04-28	股东大会：将于2022-06-21召开股东大会会议内容 ▼▲ 1.Elect six directors for a term of one year; 2.Ratify the appointment of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2022; 3.Approve an amendment to our 2015 Stock Plan to increase the number of authorized shares issuable by 3,000,000 shares; 4.Transact any other business that may properly come before the Annual Meeting or any adjournment of the Annual Meeting.
2021-09-06	温馨提示：美股因劳工节，9月6日休市一天

主营业务分析

注：通常在中报、年报时披露　

项目名称		营业收入(万美元)	收入比例(%)
按业务	产品	4577.9	100.00

项目名称		营业收入(万美元)	收入比例(%)
按业务	产品	2814.8	100.00

项目名称		营业收入(万美元)	收入比例(%)
按业务	产品	1313.9	100.00

公司新闻

热点新闻更多>>

公司公告更多>>

同花顺个股页面 | 模拟炒股 | 股民学校 | 手机炒股| 联系我们

免责声明:本信息由同花顺金融研究中心提供，仅供参考，同花顺金融研究中心力求但不保证数据的完全准确，如有错漏请以中国证监会指定上市公司信息披露媒体为准，同花顺金融研究中心不对因该资料全部或部分内容而引致的盈亏承担任何责任。用户个人对服务的使用承担风险。同花顺对此不作任何类型的担保。同花顺不担保服务一定能满足用户的要求，也不担保服务不会受中断，对服务的及时性，安全性，出错发生都不作担保。同花顺对在同花顺上得到的任何信息服务或交易进程不作担保。同花顺提供的包括同花顺理财的所有文章，数据，不构成任何的投资建议，用户查看或依据这些内容所进行的任何行为造成的风险和结果都自行负责，与同花顺无关。

【免责声明】本产品中的行情数据及资讯信息来源于第三方，长江证券不对收集数据的版权、真实性、准确性及传输过程中发生的传送错误承担法律责任。本内容仅供参考，不作为投资决策依据，长江证券不对因据此操作产生的盈亏承担任何责任。投资有风险，入市需谨慎。